Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used to treat diabetes and obesity and reduce rates of major cardiovascular events, such as stroke and myocardial infarction. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.